Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$9.10 USD
+3.13 (52.43%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $9.11 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Capricor Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 39 | 41 | 35 | 33 | 10 |
Receivables | 10 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 51 | 43 | 36 | 34 | 11 |
Net Property & Equipment | 6 | 5 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 59 | 50 | 41 | 35 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 4 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 24 | 18 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 24 | 4 | 3 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 9 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 3 | 3 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 36 | 38 | 10 | 6 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 182 | 149 | 139 | 116 | 81 |
Retained Earnings | -159 | -137 | -108 | -88 | -74 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 23 | 12 | 31 | 28 | 7 |
Total Liabilities & Shareholder's Equity | 59 | 50 | 41 | 35 | 11 |
Total Common Equity | 23 | 12 | 31 | 28 | 7 |
Shares Outstanding | 30.70 | 25.20 | 24.10 | 20.40 | 5.20 |
Book Value Per Share | 0.74 | 0.47 | 1.30 | 1.38 | 1.32 |
Fiscal Year End for Capricor Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 29 | 40 | 39 | 29 | 38 |
Receivables | 0 | 0 | 10 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 0 | 1 |
Total Current Assets | 31 | 41 | 51 | 30 | 39 |
Net Property & Equipment | 6 | 6 | 6 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 38 | 49 | 59 | 37 | 46 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 6 | 7 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 19 | 24 | 25 | 29 |
Total Current Liabilities | 22 | 26 | 31 | 33 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 1 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 3 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 31 | 36 | 39 | 43 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 191 | 187 | 182 | 157 | 155 |
Retained Earnings | -180 | -169 | -159 | -159 | -152 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 18 | 23 | -2 | 3 |
Total Liabilities & Shareholder's Equity | 38 | 49 | 59 | 37 | 46 |
Total Common Equity | 12 | 18 | 23 | -2 | 3 |
Shares Outstanding | 31.90 | 31.50 | 30.70 | 25.70 | 25.20 |
Book Value Per Share | 0.36 | 0.59 | 0.74 | -0.07 | 0.11 |